Antihistamines News and Research

RSS

Review on new, hazardous drugs of abuse presented in Journal of Addiction Medicine

The last few years have seen the emergence of a new drug problem in so-called "bath salts"-actually "designer stimulants," packaged and sold in ways that skirt drug laws. A review and update on these designer drugs is presented in the June Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine.

5 Jun 2013

Ragweed allergy sublingual immunotherapy: an interview with Dr. Peter Creticos, Johns Hopkins University School of Medicine

Ragweed is a dominant seasonal allergen in North America (~26% of US and North American population is allergic to this noxious weed which pollinates from early August to early October).

31 May 2013

Taking strong anticholinergic doubles risk of developing cognitive impairment in older adults

Research from the Regenstrief Institute, the Indiana University Center for Aging Research and Wishard-Eskenazi Health on medications commonly taken by older adults has found that drugs with strong anticholinergic effects cause cognitive impairment when taken continuously for as few as 60 days.

8 May 2013

Study investigates use of sublingual immunotherapy against ragweed allergy

An international team of researchers, led by physician-scientists at Johns Hopkins, reports that a once-daily tablet containing a high dose of a key ragweed pollen protein effectively blocks the runny noses, sneezes, nasal congestion and itchy eyes experienced by ragweed allergy sufferers.

8 May 2013

UAB expert offers simple strategies to tackle summer allergy season

Sneezing, wheezing and coughing are just some of the symptoms that seasonal allergies can stir up. One sinus expert at the University of Alabama at Birmingham said despite a late spring, the summer allergy season will be strong.

29 Apr 2013

Antihistamine drugs work by preventing histamine from attaching to H1 receptors

Itchy eyes, scratchy throat, running nose--it's allergy season! What triggers these allergic reactions, and how do allergy medications work?

26 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

3D image of cell signaling molecules indicates a trippable power switch

A three-dimensional image of one of the proteins that serves as an on-off switch as it binds to receptors on the surface of a cell suggests there may be a sort of main power switch that could be tripped. These surface receptors are responsible for helping cells discern light, set the heart racing, or detect pain.

22 Apr 2013

TSRI scientists identify new drugs for human prion disease

Human diseases caused by misfolded proteins known as prions are some of most rare yet terrifying on the planet—incurable with disturbing symptoms that include dementia, personality shifts, hallucinations and coordination problems.

4 Apr 2013

Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up.

4 Apr 2013

Report highlights ecological cost of pharmaceutical waste

Pharmaceuticals commonly found in the environment are disrupting streams, with unknown impacts on aquatic life and water quality.

2 Apr 2013

Patients taking antihistamines to suppress stomach acid are at greater risk of C. diff infection

Patients receiving antihistamines to suppress stomach acid are at greater risk of infection from Clostridium difficile, or C. diff, a common cause of diarrhea, particularly in health care settings, Mayo Clinic researchers have found.

28 Mar 2013

Oral drops are good for treating symptoms of allergies, allergic asthma in some people: Review

A scientific review of 63 published studies affirms that putting small amounts of purified grasses, ragweed, dust mites, pollen and mold, in liquid drops under the tongue is a safe and effective alternative to weekly injections of those allergens or the use of other medications, in treating symptoms of allergies and allergic asthma in some people.

27 Mar 2013

Study shows why certain drugs that interact with serotonin receptors have harmful effects

A team including scientists from The Scripps Research Institute (TSRI), the University of North Carolina at Chapel Hill and the Chinese Academy of Sciences has determined and analyzed the high-resolution atomic structures of two kinds of human serotonin receptor.

25 Mar 2013

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.

21 Mar 2013

Omalizumab scratches the itch for urticaria patients

The monoclonal antibody omalizumab seems to be effective at relieving symptoms for patients with chronic idiopathic urticaria who have not responded to H1-antihistamine therapy, report US researchers.

5 Mar 2013

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

25 Feb 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

Tiotropium delivered once daily via Respimat significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS/LABA, irrespective of their allergic status.

24 Feb 2013

Guidelines to help people with allergies during bad weather

As this winter continue to take many parts of the country on a temperature roller coaster ride—from seasonal bone-chilling cold to springlike warmth and then back again—many people find themselves reaching for pain relievers or other remedies to deal with runny noses and other symptoms associated with sinus and allergy problems.

31 Jan 2013